RE: Products might be on the shelves already More positive bits from that news in October.
Tasly will contribute 100 per cent of the cost of the Joint Venture's global research, development and product commercialization. Further, Tasly will facilitate preclinical, clinical, regulatory services, manufacturing and commercial expertise and utilize its significant sales force to commercialize the Joint Venture's products in China. Its sales force covers most Chinese hospitals, retail pharmacies and direct to consumer markets with a total of 60,000 representatives. Outside China, the Tasly sales division has a growing presence in Japan, Singapore, Malaysia, Korea, Vietnam, South Africa, Nigeria, and Kenya. In addition, Tasly U.S. announced in July that it is purchasing a 450,000 square foot facility in Rockville, MD and investingUS$40 million in the new facility for the manufacture of its cardiovascular drug in preparation for Phase III clinical trials in the U.S.
Chairman Yan of Tasly Group Stated, "The collaboration between Tasly and SemBioSys innovates the application of plant transgenic technology to the pharmaceutical, healthcare and cosmetic industries, makes its safer and more cost-effective, and paves a new path forward for agricultural based products. I believe that Tasly-SemBioSys Pharmaceuticals, Ltd., through the powerful combination of the two giants, will have very broad development prospects and expand around the globe with China's huge market potential."